IMNNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Imunon, Inc.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Aug 11, 2026
$0.98−0.04 (-3.43%)
Close on Oct 19, 2026
- Market cap
- $4.95M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -162.7% | -129.5% | -256.4% | |
| Return on assets | -55.2% | -56.7% | -131.7% | |
| Current ratio | 0.54 | 2.79 | 2.32 | |
| Debt to equity | – | 0.21 | – | |
| Net debt to EBITDA | – | 0.75× | – | |
| Interest coverage | – | -14.3× | – | |
| Capex to revenue | – | 3.8% | – | |
| Diluted shares | 0M | 2M | 2M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Imunon generated $91.09M from operations and spent $1.34M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$91.09M
Used
$1.34M
Capital expenditure$1.34M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-7179.6%
×Asset turnover0.01×
×Equity multiplier1.39×
=Return on equity, FY2022-84.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2022 | -7179.6% | 0.01× | 1.39× | -84.3% |
| FY2021 | -4153.9% | 0.01× | 1.50× | -55.8% |
| FY2020 | -4296.7% | 0.01× | 2.29× | -129.5% |
| FY2019 | -3370.3% | 0.01× | 2.40× | -95.2% |
| FY2018 | -2376.7% | 0.01× | 1.98× | -50.0% |
| FY2017 | -4080.4% | 0.01× | 2.34× | -122.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$14.50M
- Cash generatingOperating cash flow above zero-$13.90M
- Return on assets improvedROA up on the prior year-85.0% → -149.2%
- Earnings backed by cashOperating cash flow above net income-$13.90M vs -$14.50M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.67 → 2.32
- No dilutionShare count did not rise1M → 2M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –